Abstract 80P
Background
Cancer still remains one of the life-threatening diseases worldwide despite the large number of therapeutic approaches currently available. Steroidal compounds possess numerous biological activities being antitumor one of them. Oximes have also been associated with antitumor activity. Moreover, previous studies by our group demonstrated that steroidal oximes were also very potent against several types of cancer. Thus, we embarked in the design and synthesis of new steroidal oximes and evaluated their potential antitumor activity against lung, prostate, and triple-negative breast cancer cells, with the aim of finding alternative cytotoxic compounds for cancer treatment.
Methods
Compounds OX1, OX2, ExeOx and Formox and their parent compounds P1, OL2, Exe and Form were synthesized, and their cytotoxicity evaluated in H1299, PC3 and HCC1806 cell lines through SRB assay after the treatment of the cells with the compounds (1-75 μM). Cell viability, cell death profile, alterations on cell cycle and mitochondrial membrane potential were assessed by flow cytometry.
Results
All compounds decreased H1299, PC3 and HCC1806 cancer cell proliferation in a dose-dependent manner, with the exception of OX2. Overall, the parent compounds decreased cancer cell proliferation in a less pronounced way, proving that the introduction of an oxime group was beneficial for the cytotoxicity displayed. Moreover, the best compound was OX1 in all cell lines with IC50 values of 18.69, 22.90 and 29.95 μM in H1299, HCC1806 and PC3, respectively. Flow cytometry studies with OX1 showed that this compound was able to decrease cell viability in all cell lines by causing cell death mainly by apoptosis, which was accompanied by a blockage at phases G2/M and S, depending on the cell line. Considering the mitochondrial membrane potential, OX1 induced mitochondrial dysfunction, which might also be related to apoptosis.
Conclusions
Our results show that OX1 possesses a beneficial antitumor effect from the introduction of the oxime group, which is mediated by apoptosis. This effect encourages further studies on its mechanism of action and selectivity in order to discover new molecules for cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Univ Coimbra.
Funding
Foundation for Science and Technology (FCT), Portugal (Strategic Projects UID/NEU/04539/2019, UIDB/04539/2020, UIDP/04539/2020); COMPETE-FEDER (POCI-01-0145-FEDER-007440); PhD Fellowship from FCT and European Social Funding of Ana R. Gomes (UI/BD/150865/2021).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09